41 results on '"Hourcade DE"'
Search Results
2. Elucidating allergic reaction mechanisms in response to SARS-CoV-2 mRNA vaccination in adults.
- Author
-
Shah MM, Layhadi JA, Hourcade DE, Fulton WT, Tan TJ, Dunham D, Chang I, Vel MS, Fernandes A, Lee AS, Liu J, Arunachalam PS, Galli SJ, Boyd SD, Pulendran B, Davis MM, O'Hara R, Park H, Mitchell LM, Akk A, Patterson A, Jerath MR, Monroy JM, Ren Z, Kendall PL, Durham SR, Fedina A, Gibbs BF, Agache I, Chinthrajah S, Sindher SB, Heider A, Akdis CA, Shamji MH, Pham CTN, and Nadeau KC
- Subjects
- Humans, Male, Female, Adult, Middle Aged, mRNA Vaccines immunology, Vaccination adverse effects, Hypersensitivity immunology, Hypersensitivity etiology, Immunoglobulin G immunology, Immunoglobulin G blood, Aged, Immunoglobulin E immunology, Immunoglobulin E blood, COVID-19 Vaccines immunology, COVID-19 Vaccines adverse effects, COVID-19 immunology, COVID-19 prevention & control, SARS-CoV-2 immunology, Basophils immunology, Basophils metabolism, Complement Activation immunology
- Abstract
Background: During the COVID-19 pandemic, novel nanoparticle-based mRNA vaccines were developed. A small number of individuals developed allergic reactions to these vaccines although the mechanisms remain undefined., Methods: To understand COVID-19 vaccine-mediated allergic reactions, we enrolled 19 participants who developed allergic events within 2 h of vaccination and 13 controls, nonreactors. Using standard hemolysis assays, we demonstrated that sera from allergic participants induced stronger complement activation compared to nonallergic subjects following ex vivo vaccine exposure., Results: Vaccine-mediated complement activation correlated with anti-polyethelyne glycol (PEG) IgG (but not IgM) levels while anti-PEG IgE was undetectable in all subjects. Depletion of total IgG suppressed complement activation in select individuals. To investigate the effects of vaccine excipients on basophil function, we employed a validated indirect basophil activation test that stratified the allergic populations into high and low responders. Complement C3a and C5a receptor blockade in this system suppressed basophil response, providing strong evidence for complement involvement in vaccine-mediated basophil activation. Single-cell multiome analysis revealed differential expression of genes encoding the cytokine response and Toll-like receptor (TLR) pathways within the monocyte compartment. Differential chromatin accessibility for IL-13 and IL-1B genes was found in allergic and nonallergic participants, suggesting that in vivo, epigenetic modulation of mononuclear phagocyte immunophenotypes determines their subsequent functional responsiveness, contributing to the overall physiologic manifestation of vaccine reactions., Conclusion: These findings provide insights into the mechanisms underlying allergic reactions to COVID-19 mRNA vaccines, which may be used for future vaccine strategies in individuals with prior history of allergies or reactions and reduce vaccine hesitancy., (© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
3. A Monoclonal Antibody That Provides a Model for C3 Nephritic Factors.
- Author
-
Hourcade DE and Mitchell LM
- Subjects
- Animals, Mice, Properdin, Autoantibodies, Antibodies, Monoclonal, Complement C3 Nephritic Factor
- Abstract
Complement is a major innate defense system that protects the intravascular space from microbial invasion. Complement activation results in the assembly of C3 convertases, serine proteases that cleave complement protein C3, generating bioactive fragments C3a and C3b. The complement response is rapid and robust, largely due to a positive feedback regulatory loop mediated by alternative pathway (AP) C3 convertase. C3 nephritic factors (C3NEFs) are autoantibodies that stabilize AP convertase, resulting in uncontrolled C3 cleavage, which, in principle, can promote critical tissue injury similar to that seen in certain renal conditions. Investigations of C3NEFs are hampered by a challenging issue: each C3NEF is derived from a different donor source, and there is no method to compare one C3NEF to another. We have identified a widely available mouse anti-C3 mAb that, similar to many C3NEFs, can stabilize functional AP convertase in a form resistant to decay acceleration by multiple complement regulators. The antibody requires the presence of properdin to confer convertase stability, and hampers the activity of Salp20, a tic salivary protein that accelerates convertase dissociation by displacing properdin from the convertase complex. This mAb can serve as an urgently needed standard for the investigation of C3NEFs. This study also provides novel insights into the dynamics of AP convertase.
- Published
- 2023
- Full Text
- View/download PDF
4. Deep phenotyping detects a pathological CD4 + T-cell complosome signature in systemic sclerosis.
- Author
-
Arbore G, Ong VH, Costantini B, Denton CP, Abraham D, Placais L, Blighe K, Mitchell L, Ellis R, Heck S, Nocerino P, Woodruff TM, Kordasti S, Kemper C, and Hourcade DE
- Subjects
- Humans, Scleroderma, Diffuse blood, Scleroderma, Diffuse immunology, Scleroderma, Diffuse pathology, Scleroderma, Systemic blood, Scleroderma, Systemic pathology, Th1 Cells immunology, CD4-Positive T-Lymphocytes immunology, Complement System Proteins metabolism, Immunophenotyping, Scleroderma, Systemic immunology
- Published
- 2020
- Full Text
- View/download PDF
5. Complement activation on neutrophils initiates endothelial adhesion and extravasation.
- Author
-
Akk A, Springer LE, Yang L, Hamilton-Burdess S, Lambris JD, Yan H, Hu Y, Wu X, Hourcade DE, Miller MJ, and Pham CTN
- Subjects
- Animals, Antigen-Antibody Complex immunology, Autoantibodies immunology, Cells, Cultured, Female, Humans, Male, Mice, Inbred C57BL, Receptors, IgG immunology, Cell Adhesion immunology, Complement Activation immunology, Complement C5a immunology, Human Umbilical Vein Endothelial Cells immunology, Neutrophils immunology
- Abstract
Neutrophils are essential to the pathogenesis of many inflammatory diseases. In the autoantibody-mediated K/BxN model of inflammatory arthritis, the alternative pathway (AP) of complement and Fc gamma receptors (FcγRs) are required for disease development while the classical pathway is dispensable. The reason for this differential requirement is unknown. We show that within minutes of K/BxN serum injection complement activation (CA) is detected on circulating neutrophils, as evidenced by cell surface C3 fragment deposition. CA requires the AP factor B and FcγRs but not C4, implying that engagement of FcγRs by autoantibody or immune complexes directly triggers AP C3 convertase assembly. The absence of C5 does not prevent CA on neutrophils but diminishes the upregulation of adhesion molecules. In vivo two-photon microscopy reveals that CA on neutrophils is critical for neutrophil extravasation and generation of C5a at the site of inflammation. C5a stimulates the release of neutrophil proteases, which contribute to the degradation of VE-cadherin, an adherens junction protein that regulates endothelial barrier integrity. C5a receptor antagonism blocks the extracellular release of neutrophil proteases, suppressing VE-cadherin degradation and neutrophil transendothelial migration in vivo. These results elucidate the AP-dependent intravascular neutrophil-endothelial interactions that initiate the inflammatory cascade in this disease model but may be generalizable to neutrophil extravasation in other inflammatory processes., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
6. Timing and mechanism of conceptus demise in a complement regulatory membrane protein deficient mouse.
- Author
-
Triebwasser MP, Wu X, Bertram P, Hourcade DE, Nelson DM, and Atkinson JP
- Subjects
- Abortion, Spontaneous immunology, Animals, Complement C3-C5 Convertases, Alternative Pathway metabolism, Embryo, Mammalian immunology, Female, Mice, Mice, Knockout, Placenta immunology, Placenta pathology, Pregnancy, Receptors, Complement 3b, Abortion, Spontaneous genetics, Complement Activation immunology, Complement C3b immunology, Complement Pathway, Alternative immunology, Embryo, Mammalian pathology, Receptors, Complement genetics
- Abstract
Problem: Crry is a widely expressed type 1 transmembrane complement regulatory protein in rodents which protects self-tissue by downregulating C3 activation. Crry
-/- concepti produced by Crry+/- × Crry+/- matings are attacked by maternal complement system leading to loss before day 10. The membrane attack complex is not the mediator of this death. We hypothesized that the ability of C3b to engage the alternative pathway's feedback loop relatively unchecked on placental membranes induces the lesion yielding the demise of the Crry-/- mouse., Method of Study: We investigated the basis of Crry-/- conceptus demise by depleting maternal complement with cobra venom factor and blocking antibodies. We monitored their effects primarily by genotyping and histologic analyses., Results: We narrowed the critical period of the complement effect from 6.5 to 8.5 days post-coitus (dpc), which is immediately after the conceptus is exposed to maternal blood. Deposition by 5.5 dpc of maternal C3b on the placental vasculature lacking Crry-/- yielded loss of the conceptus by 8.5 dpc. Fusion of the allantois to the chorion during placental assembly did not occur, fetal vessels originating in the allantois did not infiltrate the chorioallantoic placenta, the chorionic plate failed to develop, and the labyrinthine component of the placenta did not mature., Conclusion: Our data are most consistent with the deposition of C3b being responsible for the failure of the allantois to fuse to the chorion leading to subsequent conceptus demise., (© 2018 The Authors. American Journal of Reproductive Immunology published by John Wiley & Sons Ltd.)- Published
- 2018
- Full Text
- View/download PDF
7. Contribution of Adipose-Derived Factor D/Adipsin to Complement Alternative Pathway Activation: Lessons from Lipodystrophy.
- Author
-
Wu X, Hutson I, Akk AM, Mascharak S, Pham CTN, Hourcade DE, Brown R, Atkinson JP, and Harris CA
- Subjects
- Animals, Complement Factor D analysis, Humans, Mice, Adipose Tissue metabolism, Complement Factor D metabolism, Lipodystrophy blood
- Abstract
Factor D (FD) is an essential component of the complement alternative pathway (AP). It is an attractive pharmaceutical target because it is an AP-specific protease circulating in blood. Most components of the complement activation pathways are produced by the liver, but FD is highly expressed by adipose tissue. Two critical questions are: 1) to what degree does adipose tissue contribute to circulating FD levels and 2) what quantity of FD is sufficient to maintain a functional AP? To address these issues, we studied a novel mouse strain with complete lipodystrophy (LD), the fld mouse with partial LD, an FD-deficient mouse, and samples from lipodystrophic patients. FD was undetectable in the serum of LD mice, which also showed minimal AP function. Reconstitution with purified FD, serum mixing experiments, and studies of partial LD mice all demonstrated that a low level of serum FD is sufficient for normal AP activity in the mouse system. This conclusion was further supported by experiments in which wild-type adipose precursors were transplanted into LD mice. Our results indicate that almost all FD in mouse serum is derived from adipose tissue. In contrast, FD levels were reduced ∼50% in the sera of patients with congenital generalized LD. Our studies further demonstrate that a relatively small amount of serum FD is sufficient to facilitate significant time-dependent AP activity in humans and in mice. Furthermore, this observation highlights the potential importance of obtaining nearly complete inhibition of FD in treating alternative complement activation in various autoimmune and inflammatory human diseases., (Copyright © 2018 by The American Association of Immunologists, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
8. Anti-complement activity of the Ixodes scapularis salivary protein Salp20.
- Author
-
Hourcade DE, Akk AM, Mitchell LM, Zhou HF, Hauhart R, and Pham CT
- Subjects
- Animals, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Male, Mice, Mice, Inbred C57BL, Salivary Proteins and Peptides immunology, Transfection, Complement Pathway, Alternative immunology, Ixodes immunology, Tick Infestations immunology
- Abstract
Complement, a major component of innate immunity, presents a rapid and robust defense of the intravascular space. While regulatory proteins protect host cells from complement attack, when these measures fail, unrestrained complement activation may trigger self-tissue injury, leading to pathologic conditions. Of the three complement activation pathways, the alternative pathway (AP) in particular has been implicated in numerous disease and injury states. Consequently, the AP components represent attractive targets for therapeutic intervention. The common hard-bodied ticks from the family Ixodidae derive nourishment from the blood of their mammalian hosts. During its blood meal the tick is exposed to host immune effectors, including the complement system. In defense, the tick produces salivary proteins that can inhibit host immune functions. The Salp20 salivary protein of Ixodes scapularis inhibits the host AP pathway by binding properdin and dissociating C3bBbP, the active C3 convertase. In these studies we examined Salp20 activity in various complement-mediated pathologies. Our results indicate that Salp20 can inhibit AP-dependent pathogenesis in the mouse. Its efficacy may be part in due to synergic effects it provides with the endogenous AP regulator, factor H. While Salp20 itself would be expected to be highly immunogenic and therefore inappropriate for therapeutic use, its emergence speaks for the potential development of a non-immunogenic Salp20 mimic that replicates its anti-properdin activity., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
9. Role of complement receptor 1 (CR1; CD35) on epithelial cells: A model for understanding complement-mediated damage in the kidney.
- Author
-
Java A, Liszewski MK, Hourcade DE, Zhang F, and Atkinson JP
- Subjects
- Animals, CHO Cells, Complement C4b, Complement Pathway, Alternative immunology, Cricetinae, Cricetulus, Erythrocytes metabolism, Humans, Kinetics, Opsonin Proteins metabolism, Receptors, Complement 3b chemistry, Transfection, Complement System Proteins immunology, Epithelial Cells metabolism, Kidney metabolism, Kidney pathology, Models, Immunological, Receptors, Complement 3b metabolism
- Abstract
The regulators of complement activation gene cluster encodes a group of proteins that have evolved to control the amplification of complement at the critical step of C3 activation. Complement receptor 1 (CR1) is the most versatile of these inhibitors with both receptor and regulatory functions. While expressed on most peripheral blood cells, the only epithelial site of expression in the kidney is by the podocyte. Its expression by this cell population has aroused considerable speculation as to its biologic function in view of many complement-mediated renal diseases. The goal of this investigation was to assess the role of CR1 on epithelial cells. To this end, we utilized a Chinese hamster ovary cell model system. Among our findings, CR1 reduced C3b deposition by ∼ 80% during classical pathway activation; however, it was an even more potent regulator (>95% reduction in C3b deposition) of the alternative pathway. This inhibition was primarily mediated by decay accelerating activity. The deposited C4b and C3b were progressively cleaved with a t½ of ∼ 30 min to C4d and C3d, respectively, by CR1-dependent cofactor activity. CR1 functioned intrinsically (i.e, worked only on the cell on which it was expressed). Moreover, CR1 efficiently and stably bound but didn't internalize C4b/C3b opsonized immune complexes. Our studies underscore the potential importance of CR1 on an epithelial cell population as both an intrinsic complement regulator and an immune adherence receptor. These results provide a framework for understanding how loss of CR1 expression on podocytes may contribute to complement-mediated damage in the kidney., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
10. Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers.
- Author
-
Wang K, Pan D, Schmieder AH, Senpan A, Hourcade DE, Pham CT, Mitchell LM, Caruthers SD, Cui G, Wickline SA, Shen B, and Lanza GM
- Subjects
- Animals, Biomarkers blood, Colloids, Drug Evaluation, Preclinical, Mice, Complement Activation drug effects, Contrast Media adverse effects, Contrast Media chemistry, Contrast Media pharmacology, Gadolinium adverse effects, Gadolinium chemistry, Gadolinium pharmacology, Magnetic Resonance Imaging, Manganese adverse effects, Manganese chemistry, Manganese pharmacology, Nanoparticles adverse effects, Nanoparticles chemistry
- Abstract
High-relaxivity T1-weighted (T1w) MR molecular imaging nanoparticles typically present high surface gadolinium payloads that can elicit significant acute complement activation (CA). The objective of this research was to develop a high T1w contrast nanoparticle with improved safety. We report the development, optimization, and characterization of a gadolinium-manganese hybrid nanocolloid (MnOL-Gd NC; 138±10 (Dav)/nm; PDI: 0.06; zeta: -27±2 mV). High r1 particulate relaxivity with minute additions of Gd-DOTA-lipid conjugate to the MnOL nanocolloid surface achieved an unexpected paramagnetic synergism. This hybrid MnOL-Gd NC provided optimal MR TSE signal intensity at 5 nM/voxel and lower levels consistent with the level expression anticipated for sparse biomarkers, such as neovascular integrins. MnOL NC produced optimal MR TSE signal intensity at 10 nM/voxel concentrations and above. Importantly, MnOL-Gd NC avoided acute CA in vitro and in vivo while retaining minimal transmetallation risk. From the clinical editor: The authors developed a gadolinium-manganese hybrid nanocolloid (MnOL-Gd NC) in this study. These were used as a high-relaxivity paramagnetic MR molecular imaging agent in experimental models. It was shown that MnOL-Gd NC could provide high T1w MR contrast for targeted imaging. As the level of gadolinium used was reduced, there was also reduced risk of systemic side effects from complement activation., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
11. Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.
- Author
-
Bertram P, Akk AM, Zhou HF, Mitchell LM, Pham CT, and Hourcade DE
- Subjects
- Animals, Antibodies, Monoclonal biosynthesis, Aortic Aneurysm, Abdominal chemically induced, Aortic Aneurysm, Abdominal immunology, Aortic Aneurysm, Abdominal pathology, Cricetinae, Escherichia coli genetics, Escherichia coli metabolism, Female, Gene Expression, Immunosuppressive Agents metabolism, Mice, Mice, Inbred C57BL, Pancreatic Elastase, Properdin genetics, Properdin immunology, Rabbits, Recombinant Proteins biosynthesis, Recombinant Proteins pharmacology, Antibodies, Monoclonal pharmacology, Aortic Aneurysm, Abdominal prevention & control, Complement Pathway, Alternative drug effects, Immunosuppressive Agents pharmacology, Properdin antagonists & inhibitors
- Abstract
The complement alternative pathway (AP) is a major contributor to a broad and growing spectrum of diseases that includes age-related macular degeneration, atypical hemolytic uremic syndrome, and preeclampsia. As a result, there is much interest in the therapeutic disruption of AP activity. Properdin, the only positive regulator of the AP, is a particularly promising AP target. Several issues need to be clarified before the potential for properdin-directed therapy can be realized. In this report we use a portion of the mouse properdin protein, expressed in a bacterial system, to raise rabbit polyclonal and hamster monoclonal antibodies that block properdin-dependent pathogenesis. These antibodies, when employed with AP-dependent mouse disease models, can help evaluate the feasibility of properdin-directed therapy.
- Published
- 2015
- Full Text
- View/download PDF
12. Application of a hemolysis assay for analysis of complement activation by perfluorocarbon nanoparticles.
- Author
-
Pham CT, Thomas DG, Beiser J, Mitchell LM, Huang JL, Senpan A, Hu G, Gordon M, Baker NA, Pan D, Lanza GM, and Hourcade DE
- Subjects
- Animals, Fluorocarbons chemistry, Humans, Mice, Mice, Inbred C57BL, Nanoparticles chemistry, Particle Size, Complement Activation drug effects, Fluorocarbons immunology, Hemolysis drug effects, Nanoparticles metabolism
- Abstract
Nanoparticles offer new options for medical diagnosis and therapeutics with their capacity to specifically target cells and tissues with imaging agents and/or drug payloads. The unique physical aspects of nanoparticles present new challenges for this promising technology. Studies indicate that nanoparticles often elicit moderate to severe complement activation. Using human in vitro assays that corroborated the mouse in vivo results we previously presented mechanistic studies that define the pathway and key components involved in modulating complement interactions with several gadolinium-functionalized perfluorocarbon nanoparticles (PFOB). Here we employ a modified in vitro hemolysis-based assay developed in conjunction with the mouse in vivo model to broaden our analysis to include PFOBs of varying size, charge and surface chemistry and examine the variations in nanoparticle-mediated complement activity between individuals. This approach may provide the tools for an in-depth structure-activity relationship study that will guide the eventual development of biocompatible nanoparticles., From the Clinical Editor: Unique physical aspects of nanoparticles may lead to moderate to severe complement activation in vivo, which represents a challenge to clinical applicability. In order to guide the eventual development of biocompatible nanoparticles, this team of authors report a modified in vitro hemolysis-based assay developed in conjunction with their previously presented mouse model to enable in-depth structure-activity relationship studies., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
13. Physicochemical signatures of nanoparticle-dependent complement activation.
- Author
-
Thomas DG, Chikkagoudar S, Heredia-Langer A, Tardiff MF, Xu Z, Hourcade DE, Pham CT, Lanza GM, Weinberger KQ, and Baker NA
- Abstract
Nanoparticles are potentially powerful therapeutic tools that have the capacity to target drug payloads and imaging agents. However, some nanoparticles can activate complement, a branch of the innate immune system, and cause adverse side-effects. Recently, we employed an in vi tro hemolysis assay to measure the serum complement activity of perfluorocarbon nanoparticles that differed by size, surface charge, and surface chemistry, quantifying the nanoparticle-dependent complement activity using a metric called Residual Hemolytic Activity (RHA). In the present work, we have used a decision tree learning algorithm to derive the rules for estimating nanoparticle-dependent complement response based on the data generated from the hemolytic assay studies. Our results indicate that physicochemical properties of nanoparticles, namely, size, polydispersity index, zeta potential, and mole percentage of the active surface ligand of a nanoparticle, can serve as good descriptors for prediction of nanoparticle-dependent complement activation in the decision tree modeling framework.
- Published
- 2014
- Full Text
- View/download PDF
14. Using mutagenesis and structural biology to map the binding site for the Plasmodium falciparum merozoite protein PfRh4 on the human immune adherence receptor.
- Author
-
Park HJ, Guariento M, Maciejewski M, Hauhart R, Tham WH, Cowman AF, Schmidt CQ, Mertens HD, Liszewski MK, Hourcade DE, Barlow PN, and Atkinson JP
- Subjects
- Binding Sites, Complement C3b chemistry, Complement C3b genetics, Complement C3b metabolism, Complement C4b chemistry, Complement C4b genetics, Complement C4b metabolism, Erythrocytes chemistry, Erythrocytes metabolism, Erythrocytes parasitology, HEK293 Cells, Humans, Membrane Proteins chemistry, Membrane Proteins genetics, Merozoites chemistry, Mutagenesis, Nuclear Magnetic Resonance, Biomolecular, Plasmodium falciparum chemistry, Plasmodium falciparum genetics, Protozoan Proteins chemistry, Protozoan Proteins genetics, Receptors, Complement 3b chemistry, Receptors, Complement 3b genetics, Scattering, Small Angle, Surface Plasmon Resonance, X-Ray Diffraction, Membrane Proteins metabolism, Merozoites metabolism, Plasmodium falciparum metabolism, Protozoan Proteins metabolism, Receptors, Complement 3b metabolism
- Abstract
To survive and replicate within the human host, malaria parasites must invade erythrocytes. Invasion can be mediated by the P. falciparum reticulocyte-binding homologue protein 4 (PfRh4) on the merozoite surface interacting with complement receptor type 1 (CR1, CD35) on the erythrocyte membrane. The PfRh4 attachment site lies within the three N-terminal complement control protein modules (CCPs 1-3) of CR1, which intriguingly also accommodate binding and regulatory sites for the key complement activation-specific proteolytic products, C3b and C4b. One of these regulatory activities is decay-accelerating activity. Although PfRh4 does not impact C3b/C4b binding, it does inhibit this convertase disassociating capability. Here, we have employed ELISA, co-immunoprecipitation, and surface plasmon resonance to demonstrate that CCP 1 contains all the critical residues for PfRh4 interaction. We fine mapped by homologous substitution mutagenesis the PfRh4-binding site on CCP 1 and visualized it with a solution structure of CCPs 1-3 derived by NMR and small angle x-ray scattering. We cross-validated these results by creating an artificial PfRh4-binding site through substitution of putative PfRh4-interacting residues from CCP 1 into their homologous positions within CCP 8; strikingly, this engineered binding site had an ∼30-fold higher affinity for PfRh4 than the native one in CCP 1. These experiments define a candidate site on CR1 by which P. falciparum merozoites gain access to human erythrocytes in a non-sialic acid-dependent pathway of merozoite invasion.
- Published
- 2014
- Full Text
- View/download PDF
15. Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation.
- Author
-
Zhou HF, Yan H, Bertram P, Hu Y, Springer LE, Thompson RW, Curci JA, Hourcade DE, and Pham CT
- Subjects
- Analysis of Variance, Animals, Aortic Aneurysm, Abdominal immunology, Blotting, Western, Enzyme-Linked Immunosorbent Assay, Extracellular Matrix Proteins metabolism, Fluorescent Antibody Technique, Humans, Immunoglobulin G metabolism, Immunohistochemistry, Immunoprecipitation, Mice, Mice, Inbred C57BL, Pancreatic Elastase, Aortic Aneurysm, Abdominal etiology, Complement Activation immunology, Complement Pathway, Mannose-Binding Lectin immunology, Fibrinogen immunology, Immunoglobulin G immunology
- Abstract
Abdominal aortic aneurysm (AAA) is a common vascular disease associated with high mortality rate due to progressive enlargement and eventual rupture. There is currently no established therapy known to alter the rate of aneurysmal expansion. Thus, understanding the processes that initiate and sustain aneurysmal growth is pivotal for the development of medical therapies aimed at halting disease progression. Using an elastase-induced AAA mouse model that recapitulates key features of human AAA, we previously reported that a natural IgG antibody directs alternative pathway complement activation and initiates the inflammatory process that culminates in aneurysmal development. The target of this natural antibody, however, was unknown. Herein we identify a natural IgG that binds to fibrinogen deposited in elastase-perfused aortic tissues, activates the complement lectin pathway (LP), and induces AAA. Moreover, we establish that alterations in the glycosylation patterns of this antibody critically affect its ability to activate the LP in vivo. We find that LP activation precedes the alternative pathway and absence of the LP complement protein mannan-binding lectin abrogates elastase-induced AAA. In human AAA tissues the mouse anti-fibrinogen antibody recognizes epitopes that localize to the same areas that stain positively for mannan-binding lectin, which suggests that the complement LP is engaged in humans as well. Lastly, we demonstrate that circulating antibodies in a subset of AAA patients react against fibrinogen or fibrinogen-associated epitopes in human aneurysmal tissues. Our findings support the concept that an autoimmune process directed at aortic wall self-antigens may play a central role in the immunopathogenesis of AAA.
- Published
- 2013
- Full Text
- View/download PDF
16. Detection of complement activation using monoclonal antibodies against C3d.
- Author
-
Thurman JM, Kulik L, Orth H, Wong M, Renner B, Sargsyan SA, Mitchell LM, Hourcade DE, Hannan JP, Kovacs JM, Coughlin B, Woodell AS, Pickering MC, Rohrer B, and Holers VM
- Subjects
- Animals, Biomarkers metabolism, Choroidal Neovascularization metabolism, Complement C3-C5 Convertases immunology, Complement C3d physiology, Epitopes immunology, Humans, Inflammation, Mice, Mice, Inbred C57BL, Protein Binding, Recombinant Proteins immunology, Spleen cytology, Surface Plasmon Resonance, Antibodies, Monoclonal, Murine-Derived immunology, Complement Activation, Complement C3d immunology
- Abstract
During complement activation the C3 protein is cleaved, and C3 activation fragments are covalently fixed to tissues. Tissue-bound C3 fragments are a durable biomarker of tissue inflammation, and these fragments have been exploited as addressable binding ligands for targeted therapeutics and diagnostic agents. We have generated cross-reactive murine monoclonal antibodies against human and mouse C3d, the final C3 degradation fragment generated during complement activation. We developed 3 monoclonal antibodies (3d8b, 3d9a, and 3d29) that preferentially bind to the iC3b, C3dg, and C3d fragments in solution, but do not bind to intact C3 or C3b. The same 3 clones also bind to tissue-bound C3 activation fragments when injected systemically. Using mouse models of renal and ocular disease, we confirmed that, following systemic injection, the antibodies accumulated at sites of C3 fragment deposition within the glomerulus, the renal tubulointerstitium, and the posterior pole of the eye. To detect antibodies bound within the eye, we used optical imaging and observed accumulation of the antibodies within retinal lesions in a model of choroidal neovascularization (CNV). Our results demonstrate that imaging methods that use these antibodies may provide a sensitive means of detecting and monitoring complement activation-associated tissue inflammation.
- Published
- 2013
- Full Text
- View/download PDF
17. Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm.
- Author
-
Zhou HF, Yan H, Stover CM, Fernandez TM, Rodriguez de Cordoba S, Song WC, Wu X, Thompson RW, Schwaeble WJ, Atkinson JP, Hourcade DE, and Pham CT
- Subjects
- Animals, Anti-Bacterial Agents pharmacology, Complement Activation drug effects, Mice, Aortic Aneurysm, Abdominal metabolism, Complement System Proteins metabolism, Disease Models, Animal, Properdin metabolism
- Abstract
Abdominal aortic aneurysm (AAA) is a complex inflammatory vascular disease. There are currently limited treatment options for AAA when surgery is inapplicable. Therefore, insights into molecular mechanisms underlying AAA pathogenesis may reveal therapeutic targets that could be manipulated pharmacologically or biologically to halt disease progression. Using an elastase-induced AAA mouse model, we previously established that the complement alternative pathway (AP) plays a critical role in the development of AAA. However, the mechanism by which complement AP is initiated remains undefined. The complement protein properdin, traditionally viewed as a positive regulator of the AP, may also initiate complement activation by binding directly to target surfaces. In this study, we sought to determine whether properdin serves as a focal point for the initiation of the AP complement activation in AAA. Using a properdin loss of function mutation in mice and a mutant form of the complement factor B protein that produces a stable, properdin-free AP C3 convertase, we show that properdin is required for the development of elastase-induced AAA in its primary role as a convertase stabilizer. Unexpectedly, we find that, in AAA, natural IgG antibodies direct AP-mediated complement activation. The absence of IgG abrogates C3 deposition in elastase-perfused aortic wall and protects animals from AAA development. We also determine that blockade of properdin activity prevents aneurysm formation. These results indicate that an innate immune response to self-antigens activates the complement system and initiates the inflammatory cascade in AAA. Moreover, the study suggests that properdin-targeting strategies may halt aneurysmal growth.
- Published
- 2012
- Full Text
- View/download PDF
18. Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein.
- Author
-
Hourcade DE and Mitchell LM
- Subjects
- Amino Acid Substitution, Complement C3b genetics, Complement C3b metabolism, Complement Factor B genetics, Complement Factor B metabolism, Complement Factor D genetics, Complement Factor D metabolism, Humans, Multienzyme Complexes genetics, Multienzyme Complexes metabolism, Mutation, Missense, Protein Binding, Complement C3b chemistry, Complement Factor B chemistry, Complement Factor D chemistry, Multienzyme Complexes chemistry
- Abstract
Factor B is a zymogen that carries the catalytic site of the complement alternative pathway C3 convertase. During convertase assembly, factor B associates with C3b and Mg(2+) forming a pro-convertase C3bB(Mg(2+)) that is cleaved at a single factor B site by factor D. In free factor B, a pair of salt bridges binds the Arg(234) side chain to Glu(446) and to Glu(207), forming a double latch structure that sequesters the scissile bond (between Arg(234) and Lys(235)) and minimizes its unproductive cleavage. It is unknown how the double latch is released in the pro-convertase. Here, we introduce single amino acid substitutions into factor B that preclude one or both of the Arg(234) salt bridges, and we examine their impact on several different pro-convertase complexes. Our results indicate that loss of the Arg(234)-Glu(446) salt bridge partially stabilizes C3bB(Mg(2+)). Loss of the Arg(234)-Glu(207) salt bridge has lesser effects. We propose that when factor B first associates with C3b, it bears two intact Arg(234) salt bridges. The complex rapidly dissociates unless the Arg(234)-Glu(446) salt bridge is released whereupon conformational changes occur that activate the metal ion-dependent adhesion site and partially stabilize the complex. The remaining salt bridge is then released, exposing the scissile bond and permitting factor D cleavage.
- Published
- 2011
- Full Text
- View/download PDF
19. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.
- Author
-
Pham CT, Mitchell LM, Huang JL, Lubniewski CM, Schall OF, Killgore JK, Pan D, Wickline SA, Lanza GM, and Hourcade DE
- Subjects
- Animals, Drug Design, Gadolinium chemistry, Humans, Immunoglobulin M immunology, Mice, Nanocapsules adverse effects, Surface Properties, Antibodies immunology, Complement System Proteins immunology, Nanocapsules chemistry, Phospholipids
- Abstract
A wide variety of nanomaterials are currently being developed for use in the detection and treatment of human diseases. However, there is no systematic way to measure and predict the action of such materials in biological contexts. Lipid-encapsulated nanoparticles (NPs) are a class of nanomaterials that includes the liposomes, the most widely used and clinically proven type of NPs. Liposomes can, however, activate the complement system, an important branch of innate immunity, resulting in undesirable consequences. Here, we describe the complement response to lipid-encapsulated NPs that are functionalized on the surface with various lipid-anchored gadolinium chelates. We developed a quantitative approach to examine the interaction of NPs with the complement system using in vitro assays and correlating these results with those obtained in an in vivo mouse model. Our results indicate that surface functionalization of NPs with certain chemical structures elicits swift complement activation that is initiated by a natural IgM antibody and propagated via the classical pathway. The intensity of the response is dependent on the chemical structures of the lipid-anchored chelates and not zeta potential effects alone. Moreover, the extent of complement activation may be tempered by complement inhibiting regulatory proteins that bind to the surface of NPs. These findings represent a step forward in the understanding of the interactions between nanomaterials and the host innate immune response and provide the basis for a systematic structure-activity relationship study to establish guidelines that are critical to the future development of biocompatible nanotherapeutics.
- Published
- 2011
- Full Text
- View/download PDF
20. Oversulfated heparin by-products induce thrombin generation in human plasmas through contact system activation.
- Author
-
Yi Qian, Jing Pan, Xiaodong Zhou, Hourcade DE, Liszewski MK, Atkinson JP, Hong Lu, and Lijuan Zhang
- Subjects
- Anaphylaxis blood, Anaphylaxis chemically induced, Anticoagulants analysis, Chondroitin Sulfates adverse effects, Chondroitin Sulfates analysis, Coagulation Protein Disorders blood, Disease Outbreaks, Drug Contamination, Enzyme Activation drug effects, Fibrinogen drug effects, Heparin analysis, Humans, Kallikreins blood, Phosphatidylethanolamines pharmacology, Prekallikrein drug effects, Prekallikrein metabolism, Prothrombin metabolism, Silicon Dioxide pharmacology, Anticoagulants pharmacology, Blood Coagulation drug effects, Chondroitin Sulfates pharmacology, Heparin pharmacology, Thrombin biosynthesis
- Abstract
Thrombin generation is thought to be mediated predominantly by the tissue factor or ''extrinsic'' coagulation pathway. An alternate pathway to thrombin generation (the ''intrinsic'' pathway or contact system) has been observed when blood or plasma comes in contact with artificial surfaces. Here we present evidence for a new route to thrombin formation that begins with the activation of the contact system protein prekallikrein by oversulfated heparin (OS-HB). Kallikrein, instead of activated factor X, cleaves prothrombin to form thrombin. Thrombin then cleaves fibrinogen to form fibrin clots. Moreover, we show that OS-HB by-products induce kallikrein- and thrombin-like activities in normal human plasma and in human plasma devoid of coagulation factor X or downstream contact system components factor IX or factor XI. Oversulfated heparin by-product-induced thrombin generation may have had a role in the adverse reactions associated with the recent clinical use of contaminated heparin.
- Published
- 2010
- Full Text
- View/download PDF
21. Properdin: emerging roles of a pattern-recognition molecule.
- Author
-
Kemper C, Atkinson JP, and Hourcade DE
- Subjects
- Animals, Autoimmune Diseases immunology, Complement Activation, Complement System Proteins immunology, Humans, Inflammation immunology, Neutrophils immunology, Properdin chemistry, Properdin immunology
- Abstract
Complement is an innate immune system that is a first line of defense against pathogens and facilitates elimination of apoptotic and injured cells. During complement activation, the complement convertases are assembled on target surfaces and initiate their proteolytic activities, a process that marks targets for phagocytosis and/or lysis. The complement alternative activation pathway has been implicated in a number of autoimmune conditions including arthritis and age-related macular degeneration. Properdin, a plasma component that is also released by activated neutrophils, is critical in the stabilization of alternative pathway convertases. Recently, it has been shown that properdin is also a pattern-recognition molecule that binds to certain microbial surfaces, apoptotic cells, and necrotic cells. Once bound to a surface, properdin can direct convertase formation and target uptake. New studies are now focusing on a role for properdin in inflammatory and autoimmune diseases. This review examines the new properdin findings and their implications.
- Published
- 2010
- Full Text
- View/download PDF
22. Properdin: New roles in pattern recognition and target clearance.
- Author
-
Kemper C and Hourcade DE
- Subjects
- Animals, Complement System Proteins metabolism, Humans, Models, Immunological, Properdin metabolism, Complement Pathway, Alternative immunology, Complement System Proteins immunology, Properdin immunology
- Abstract
Properdin was first described over 50 years ago by Louis Pillemer and his collaborators as a vital component of an antibody-independent complement activation pathway. In the 1970s properdin was shown to be a stabilizing component of the alternative pathway convertases, the central enzymes of the complement cascade. Recently we have reported that properdin can also bind to target cells and microbes, provide a platform for convertase assembly and function, and promote target phagocytosis. Evidence is emerging that suggests that properdin interacts with a network of target ligands, phagocyte receptors, and serum regulators. Here we review the new findings and their possible implications.
- Published
- 2008
- Full Text
- View/download PDF
23. The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis.
- Author
-
Kemper C, Mitchell LM, Zhang L, and Hourcade DE
- Subjects
- CD4-Positive T-Lymphocytes pathology, Complement C3b immunology, Dendritic Cells immunology, Glycosaminoglycans immunology, Humans, Macrophages immunology, Neutrophils immunology, Phagocytes cytology, Phagocytes immunology, Protein Binding, Proteoglycans immunology, Apoptosis, CD4-Positive T-Lymphocytes cytology, CD4-Positive T-Lymphocytes immunology, Complement Activation immunology, Phagocytosis immunology, Properdin immunology
- Abstract
Apoptotic cells must be rapidly eliminated to avoid harmful inflammatory and autoimmune reactions. Innate immunity is designed/poised to identify dying cells by their unique surface-associated molecular patterns. Here we demonstrate for the first time, to our knowledge, that the human complement protein properdin binds to early apoptotic T cells and initiates complement activation, leading to C3b opsonization and ingestion by phagocytic cells. Properdin binding was facilitated by the glycosaminoglycan chains of surface proteoglycans. Properdin released by activated neutrophils was particularly effective at recognition of apoptotic T cells, whereas the binding activity of properdin in the serum appeared to be inhibited. "Properdin tagging" of apoptotic T cells also induced their uptake by phagocytes independent of complement activation or other complement proteins. Although our findings were made primarily with apoptotic T cells, they suggest that properdin could play a similar role during apoptosis of other cell types.
- Published
- 2008
- Full Text
- View/download PDF
24. Evidence for non-traditional activation of complement factor C3 during murine liver regeneration.
- Author
-
Clark A, Weymann A, Hartman E, Turmelle Y, Carroll M, Thurman JM, Holers VM, Hourcade DE, and Rudnick DA
- Subjects
- Animals, Antibodies, Monoclonal immunology, Complement C3 deficiency, Complement C4 deficiency, Complement C4 immunology, Complement Factor B deficiency, Complement Factor B immunology, Immunoblotting, Liver cytology, Liver immunology, Mice, Mice, Inbred C57BL, Neutralization Tests, Protein Processing, Post-Translational, Complement Activation, Complement C3 immunology, Liver Regeneration immunology
- Abstract
Unlabelled: Complement signaling has been implicated as important for normal hepatic regeneration. However, the specific mechanism by which complement is activated during liver regeneration remains undefined. To address this question, we investigated the hepatic regenerative response to partial hepatectomy in wildtype mice, C3-, C4-, and factor B-null mice, and C4-null mice treated with a factor B neutralizing antibody (mAb 1379). The results showed that following partial hepatectomy, C3-null mice exhibit reduced hepatic regeneration compared to wildtype mice as assessed by quantification of hepatic cyclin D1 expression and hepatocellular DNA synthesis and mitosis. In contrast, C4-null mice and factor B-null mice demonstrated normal liver regeneration. Moreover, animals in which all of the traditional upstream C3 activation pathways were disrupted, i.e. C4-null mice treated with mAb 1379, exhibited normal C3 activation and hepatocellular proliferation following partial hepatectomy. In order to define candidate non-traditional mechanisms of C3 activation during liver regeneration, plasmin and thrombin were investigated for their abilities to activate C3 in mouse plasma in vitro. The results showed that both proteases are capable of initiating C3 activation, and that plasmin can do so independent of the classical and alternative pathways., Conclusions: These results show that C3 is required for a normal hepatic regenerative response, but that disruption of the classical- or lectin-dependent pathways (C4-dependent), the alternative pathway (factor B-dependent), or all of these pathways does not impair the hepatic regenerative response, and indicate that non-traditional mechanisms by which C3 is activated during hepatic regeneration must exist. In vitro analysis raises the possibility that plasmin may contribute to non-traditional complement activation during liver regeneration in vivo.
- Published
- 2008
- Full Text
- View/download PDF
25. Properdin and complement activation: a fresh perspective.
- Author
-
Hourcade DE
- Subjects
- Animals, Autoimmune Diseases drug therapy, Autoimmune Diseases physiopathology, Bacteria pathogenicity, Complement Activation physiology, Drug Delivery Systems, Humans, Complement C3-C5 Convertases metabolism, Complement Pathway, Alternative immunology, Properdin immunology
- Abstract
The C3 convertases are the major proteases of the complement cascade and are assembled at the site of complement activation via several different pathways. Properdin's functional role in stabilizing the alternative pathway convertase has been long established; however, new evidence demonstrates that properdin can also bind to certain microbial surfaces, and provide a platform for de novo convertase assembly. Therefore, properdin participates in two distinct mechanisms for complement activation: the alternative pathway and a properdin-directed pathway. Previous work had implicated the alternative pathway in the initiation and/or progression of several autoimmune diseases and in the host defense against certain bacterial pathogens. Those conclusions were based on evidence that cannot distinguish effects of the alternative pathway from effects of the properdin-directed pathway. With the identification of the new role for properdin in C3 convertase assembly there became a pressing need to reassess the mechanisms of complement activation, determine the specific role of properdin in each of these pathways, and explore the new therapeutic avenues that could arise.
- Published
- 2008
- Full Text
- View/download PDF
26. The Quantification of Glycosaminoglycans: A Comparison of HPLC, Carbazole, and Alcian Blue Methods.
- Author
-
Frazier SB, Roodhouse KA, Hourcade DE, and Zhang L
- Abstract
Glycosaminoglycans (GAGs) are linear polysaccharides that are found in the extracellular matrix and biological fluids of animals where they interact with hundreds of proteins and perform a variety of critical roles. There are five classes of animal GAGs: heparan sulfate (HS), chondroitin sulfate (CS), dermatan sulfate (DS), keratan sulfate (KS), and hyaluronan (HA). Many biological functions can be monitored directly by their impact on GAG quantity. Thus, simple, sensitive, and robust GAG quantification methods are needed for the development of biomarkers. We have systematically compared three available GAG quantification assays including an HPLC-based assay, a simplified Alcian Blue assay, and a miniaturized carbazole assay. The carbazole and Alcian Blue assays were reproducible and simple to perform in general lab settings, but had important limitations: The carbazole assay could not detect KS and it overestimated GAGs that were contaminated with salts or dissolved in PBS. The Alcian Blue assay detected only those GAGs that were sulfated. In contrast, while the HPLC method was time-consuming, it was a robust and sensitive assay that not only detected all GAGs but also quantified glucosamine-GAGs and galactosamine-GAGs simultaneously. The HPLC assay was not affected by salt or level of GAG sulfation and it yielded reproducible values for all types of GAGs tested. These results suggest that an automated HPLC assay would be generally useful for the routine measurement of a panel of GAG-based biomarkers while the carbazole assay and the Alcian Blue assays could prove valuable for more specific purposes.
- Published
- 2008
- Full Text
- View/download PDF
27. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly.
- Author
-
Spitzer D, Mitchell LM, Atkinson JP, and Hourcade DE
- Subjects
- Animals, Antibodies chemistry, Antibodies genetics, Antibodies metabolism, Complement C3 Convertase, Alternative Pathway metabolism, Escherichia coli Infections genetics, Escherichia coli Infections metabolism, Escherichia coli K12 genetics, Escherichia coli K12 metabolism, Gonorrhea metabolism, Humans, Lipopolysaccharides metabolism, Mutation, Neisseria gonorrhoeae metabolism, Properdin genetics, Properdin metabolism, Protein Binding, Rabbits, Recombinant Fusion Proteins chemistry, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Sheep, U937 Cells, Zymosan metabolism, Complement C3 Convertase, Alternative Pathway chemistry, Complement Pathway, Alternative, Escherichia coli K12 chemistry, Lipopolysaccharides chemistry, Neisseria gonorrhoeae chemistry, Properdin chemistry, Zymosan chemistry
- Abstract
Complement promotes the rapid recognition and elimination of pathogens, infected cells, and immune complexes. The biochemical basis for its target specificity is incompletely understood. In this report, we demonstrate that properdin can directly bind to microbial targets and provide a platform for the in situ assembly and function of the alternative pathway C3 convertases. This mechanism differs from the standard model wherein nascent C3b generated in the fluid phase attaches nonspecifically to its targets. Properdin-directed complement activation occurred on yeast cell walls (zymosan) and Neisseria gonorrhoeae. Properdin did not bind wild-type Escherichia coli, but it readily bound E. coli LPS mutants, and the properdin-binding capacity of each strain correlated with its respective serum-dependent AP activation rate. Moreover, properdin:single-chain Ab constructs were used to direct serum-dependent complement activation to novel targets. We conclude properdin participates in two distinct complement activation pathways: one that occurs by the standard model and one that proceeds by the properdin-directed model. The properdin-directed model is consistent with a proposal made by Pillemer and his colleagues >50 years ago.
- Published
- 2007
- Full Text
- View/download PDF
28. Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases.
- Author
-
Kuttner-Kondo L, Hourcade DE, Anderson VE, Muqim N, Mitchell L, Soares DC, Barlow PN, and Medof ME
- Subjects
- Amino Acid Sequence, Animals, Binding Sites, CD55 Antigens metabolism, Complement C3-C5 Convertases metabolism, Crystallography, X-Ray, Epitopes chemistry, Humans, Leucine chemistry, Models, Molecular, Molecular Sequence Data, Mutation, Phenylalanine chemistry, Protein Binding, Sequence Homology, Amino Acid, CD55 Antigens chemistry, Complement C3-C5 Convertases chemistry
- Abstract
Focused complement activation on foreign targets depends on regulatory proteins that decay the bimolecular C3 convertases. Although this process is central to complement control, how the convertases engage and disassemble is not established. The second and third complement control protein (CCP) modules of the cell surface regulator, decay-accelerating factor (DAF, CD55), comprise the simplest structure mediating this activity. Positioning the functional effects of 31 substitution mutants of DAF CCP2 to -4 on partial structures was previously reported. In light of the high resolution crystal structure of the DAF four-CCP functional region, we now reexamine the effects of these and 40 additional mutations. Moreover, we map six monoclonal antibody epitopes and overlap their effects with those of the amino acid substitutions. The data indicate that the interaction of DAF with the convertases is mediated predominantly by two patches approximately 13 A apart, one centered around Arg69 and Arg96 on CCP2 and the other around Phe148 and Leu171 on CCP3. These patches on the same face of the adjacent modules bracket an intermodular linker of critical length (16 A.) Although the key DAF residues in these patches are present or there are conservative substitutions in all other C3 convertase regulators that mediate decay acceleration and/or provide factor I-cofactor activity, the linker region is highly conserved only in the former. Intra-CCP regions also differ. Linker region comparisons suggest that the active CCPs of the decay accelerators are extended, whereas those of the cofactors are tilted. Intra-CCP comparisons suggest that the two classes of regulators bind different regions on their respective ligands.
- Published
- 2007
- Full Text
- View/download PDF
29. The decay accelerating factor mutation I197V found in hemolytic uraemic syndrome does not impair complement regulation.
- Author
-
Kavanagh D, Burgess R, Spitzer D, Richards A, Diaz-Torres ML, Goodship JA, Hourcade DE, Atkinson JP, and Goodship TH
- Subjects
- Complement Factor H genetics, DNA Mutational Analysis, Family Health, Fibrinogen, Hemolytic-Uremic Syndrome etiology, Humans, Membrane Cofactor Protein genetics, Models, Molecular, Mutation, CD55 Antigens genetics, Complement System Proteins genetics, Hemolytic-Uremic Syndrome genetics, Mutation, Missense
- Abstract
Hemolytic uremic syndrome is the clinical triad of thrombocytopenia, microangiopathic hemolytic anaemia and acute renal failure. Cases not associated with a preceding Shiga-like toxin producing Escherichia coli are described as atypical HUS (aHUS). Approximately 50% of patients with aHUS have mutations in one of three complement regulatory proteins, Factor H (CFH), membrane cofactor protein (MCP;CD46) or factor I (IF). A common feature of these three proteins is that they regulate complement by cofactor activity. Decay accelerating factor (DAF; CD55) regulates the complement system by disassociating the alternative and classical pathway convertases. Like CFH and MCP, the gene for DAF lies within the regulators of complement activation (RCA) gene cluster at 1q32. In 1998, we described linkage to this region in families with aHUS which led to the discovery of mutations in CFH and MCP. We therefore genotyped DAF in a panel of 46 aHUS patients including families with linkage to the RCA cluster. A mutation, I197V, was identified in one patient with familial HUS which was not found in 100 healthy controls. Molecular modelling of this mutation shows that the I197V mutation does not reside in an area which would be predicted to be important in decay accelerating activity. The expression of I197V on EBV-transformed B lymphocytes was equivalent to that of wild type controls. There was no significant decrease in decay acceleration activity of the recombinantly produced I197V mutant compared with wild type, as measured by a complement-mediated lytic assay. In conclusion, this study, identifies only one mutation in DAF in 46 patients with aHUS. This mutation, I197V, does not impair complement regulation and cannot be implicated in the pathogenesis of aHUS in this patient. This suggests that the complement regulatory abnormality in aHUS is principally one of deficient cofactor activity rather than of decay acceleration activity.
- Published
- 2007
- Full Text
- View/download PDF
30. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
- Author
-
Hourcade DE
- Subjects
- Binding Sites, Biosensing Techniques, Complement Activation, Complement System Proteins chemistry, Humans, Ligands, Models, Biological, Properdin chemistry, Properdin metabolism, Protein Binding, Protein Structure, Tertiary, Serine Endopeptidases chemistry, Surface Plasmon Resonance, Surface Properties, Time Factors, Complement C3-C5 Convertases chemistry, Properdin physiology
- Abstract
Complement is a powerful host defense system that contributes to both innate and acquired immunity. There are three pathways of complement activation, the classical pathway, lectin pathway, and alternative pathway. Each generates a C3 convertase, a serine protease that cleaves the central complement protein, C3. Nearly all the biological consequences of complement are dependent on the resulting cleavage products. Properdin is a positive regulator of complement activation that stabilizes the alternative pathway convertases (C3bBb). Properdin is composed of multiple identical protein subunits, with each subunit carrying a separate ligand-binding site. Previous reports suggest that properdin function depends on multiple interactions between its subunits with its ligands. In this study I used surface plasmon resonance assays to examine properdin interactions with C3b and factor B. I demonstrated that properdin promotes the association of C3b with factor B and provides a focal point for the assembly of C3bBb on a surface. I also found that properdin binds to preformed alternative pathway C3 convertases. These findings support a model in which properdin, bound to a target surface via C3b, iC3b, or other ligands, can use its unoccupied C3b-binding sites as receptors for nascent C3b, bystander C3b, or pre-formed C3bB and C3bBb complexes. New C3bP and C3bBP intermediates can lead to in situ assembly of C3bBbP. The full stabilizing effect of properdin on C3bBb would be attained as properdin binds more than one ligand at a time, forming a lattice of properdin: ligand interactions bound to a surface scaffold.
- Published
- 2006
- Full Text
- View/download PDF
31. A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases.
- Author
-
Kuttner-Kondo LA, Dybvig MP, Mitchell LM, Muqim N, Atkinson JP, Medof ME, and Hourcade DE
- Subjects
- Amino Acid Sequence, Binding Sites, Cell Line, Complement C3-C5 Convertases metabolism, Dose-Response Relationship, Drug, Glycoproteins chemistry, Humans, Models, Molecular, Molecular Sequence Data, Mutation, Protein Binding, Protein Conformation, Protein Structure, Tertiary, Receptors, Complement 3b chemistry, Sequence Homology, Amino Acid, Complement C3-C5 Convertases chemistry, Complement Inactivator Proteins, Tyrosine chemistry
- Abstract
The cleavage of C3 by the C3 convertases (C3bBb and C4b2a) determines whether complement activation proceeds. Dissociation (decay acceleration) of these central enzymes by the regulators decay-accelerating factor (DAF), complement receptor 1 (CR1), factor H, and C4-binding protein (C4BP) controls their function. In a previous investigation, we obtained evidence implicating the alpha4/5 region of the type A domain of Bb (especially Tyr338) in decay acceleration of C3bBb and proposed this site as a potential interaction point with DAF and long homologous repeat A of CR1. Because portions of only two DAF complement control protein domains (CCPs), CCP2 and CCP3, are necessary to mediate its decay of the CP C3 convertase (as opposed to portions of at least three CCPs in all other cases, e.g. CCPs 1-3 of CR1), DAF/C4b2a provides the simplest structural model for this reaction. Therefore, we examined the importance of the C2 alpha4/5 site on decay acceleration of C4b2a. Functional C4b2a complexes made with the C2 Y327A mutant, the C2 homolog to factor B Y338A, were highly resistant to DAF, C4BP, and long homologous repeat A of CR1, whereas C2 substitutions in two nearby residues (N324A and L328A) resulted in partial resistance. Our new findings indicate that the alpha4/5 region of C2a is critical to decay acceleration mediated by DAF, C4BP, and CR1 and suggest that decay acceleration of C4b2a and C3bBb requires interaction of the convertase alpha4/5 region with a CCP2/CCP3 site of DAF or structurally homologous sites of CR1 and C4BP.
- Published
- 2003
- Full Text
- View/download PDF
32. Expansion of the Knops blood group system and subdivision of Sl(a).
- Author
-
Moulds JM, Zimmerman PA, Doumbo OK, Diallo DA, Atkinson JP, Krych-Goldberg M, Hourcade DE, and Moulds JJ
- Subjects
- Amino Acid Sequence, Antigens, Surface chemistry, Antigens, Surface immunology, Asian People, Black People, Blood Group Antigens immunology, Cloning, Molecular, Consensus Sequence, Epitopes chemistry, Heterozygote, Homozygote, Humans, Isoantibodies blood, Models, Molecular, Molecular Sequence Data, Mutagenesis, Site-Directed, Mutation, Nucleic Acid Hybridization, Oligonucleotide Probes, Polymerase Chain Reaction, Receptors, Complement chemistry, Receptors, Complement immunology, Repetitive Sequences, Amino Acid, Sequence Analysis, DNA, White People, Antigens, Surface genetics, Blood Group Antigens genetics, Receptors, Complement genetics
- Abstract
Background: Complement receptor type 1 (CR1), which bears the Knops (Kn [KN]) blood group antigens, is involved in the rosetting of Plasmodium falciparum- infected RBCs with uninfected cells. As a first step in understanding this interaction, the molecular basis for the blood group antigens encoded by CR1 was investigated., Study Design and Methods: An antibody from a white donor who exhibited an apparent anti-Sl(a) was used for population studies of several racial groups. The donor's genomic DNA was sequenced to identify the Sl(a) mutation and other mutations., Results: The donor with anti-Sl(a) typed as Sl(a+) with some sera and had the CR1 genotype AA at bp 4828 (R1601). However, she was homozygous for a new mutation (GG) at bp 4855 changing amino acid 1610 from S1610 to T1610 (S1610T). This mutation occurred in heterozygous form in eight white and one Asian donor. The site is only nine amino acids from the previously described Sl(a) polymorphism and appears to produce a new conformational epitope., Conclusion: The antigen formerly known as Sl(a) can now be subdivided. A new terminology is proposed that recognizes both linear and conformational epitopes on the CR1 protein. At amino acid 1601, Sl 1 (Sl(a)) is represented by R, Sl 2 (Vil) is represented by glycine, and Sl 3 requires both R1601 and S1610. Sl 4 and Sl 5 are hypothetical epitopes represented by S1610 and T1610, respectively.
- Published
- 2002
- Full Text
- View/download PDF
33. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.
- Author
-
Hourcade DE, Mitchell L, Kuttner-Kondo LA, Atkinson JP, and Medof ME
- Subjects
- Cell Line, Complement C3-C5 Convertases chemistry, Complement C3-C5 Convertases genetics, Culture Media, Serum-Free, Humans, Models, Molecular, Multienzyme Complexes, Mutagenesis, Site-Directed, Protein Structure, Tertiary, CD55 Antigens metabolism, Complement C3-C5 Convertases metabolism, Complement Factor H metabolism, Receptors, Complement metabolism
- Abstract
The AP C3 convertase, C3bBb(Mg(2+)), is subject to irreversible dissociation (decay acceleration) by three proteins: DAF, CR1, and factor H. We have begun to map the factor B (fB) sites critical to these interactions. We generated a panel of fB mutations, focusing on the type A domain because it carries divalent cation and C3b-binding elements. C3bBb complexes were assembled with the mutants and subjected to decay acceleration. Two critical fB sites were identified with a structural model. 1) Several mutations centered at adjacent alpha helices 4 and 5 (Gln-335, Tyr-338, Ser-339, Asp-382) caused substantial resistance to DAF and CR1-mediated decay acceleration but not factor H. 2) Several mutations centered at the alpha 1 helix and adjoining loops (especially D254G) caused resistance to decay acceleration mediated by all three regulators and also increased C3b-binding affinity and C3bBb stability. In the simplest interpretation of these results, DAF and CR1 directly interact with C3bBb at alpha 4/5; factor H likely interacts at some other location, possibly on the C3b subunit. Mutations at the C3b.Bb interface interfere with the normal dissociation of C3b from Bb, whether it is spontaneous or promoted by DAF, CR1, or factor H.
- Published
- 2002
- Full Text
- View/download PDF
34. Characterization of the active sites in decay-accelerating factor.
- Author
-
Kuttner-Kondo LA, Mitchell L, Hourcade DE, and Medof ME
- Subjects
- Amino Acid Sequence, Amino Acid Substitution genetics, Amino Acid Substitution immunology, Animals, Antigens, CD chemistry, Binding Sites immunology, CD55 Antigens genetics, Complement C3-C5 Convertases antagonists & inhibitors, Complement C3-C5 Convertases metabolism, Complement Inactivator Proteins chemistry, Complement Inactivator Proteins genetics, Complement Inactivator Proteins metabolism, Complement Pathway, Classical genetics, Genetic Variation immunology, Humans, Macaca mulatta, Membrane Cofactor Protein, Membrane Glycoproteins chemistry, Models, Molecular, Molecular Sequence Data, Mutagenesis, Site-Directed, Repetitive Sequences, Amino Acid, Sequence Homology, Amino Acid, Viral Proteins chemistry, CD55 Antigens chemistry, CD55 Antigens metabolism
- Abstract
Decay-accelerating factor (DAF) is a complement regulator that dissociates autologous C3 convertases, which assemble on self cell surfaces. Its activity resides in the last three of its four complement control protein repeats (CCP2-4). Previous modeling on the nuclear magnetic resonance structure of CCP15-16 in the serum C3 convertase regulator factor H proposed a positively charged surface area on CCP2 extending into CCP3, and hydrophobic moieties between CCPs 2 and 3 as being primary convertase-interactive sites. To map the residues providing for the activity of DAF, we analyzed the functions of 31 primarily alanine substitution mutants based in part on this model. Replacing R69, R96, R100, and K127 in the positively charged CCP2-3 groove or hydrophobic F148 and L171 in CCP3 markedly impaired the function of DAF in both activation pathways. Significantly, mutations of K126 and F169 and of R206 and R212 in downstream CCP4 selectively reduced alternative pathway activity without affecting classical pathway activity. Rhesus macaque DAF has all the above human critical residues except for F169, which is an L, and its CCPs exhibited full activity against the human classical pathway C3 convertase. The recombinants whose function was preferentially impaired against the alternative pathway C3bBb compared with the classical pathway C4b2a were tested in classical pathway C5 convertase (C4b2a3b) assays. The effects on C4b2a and C4b2a3b were comparable, indicating that DAF functions similarly on the two enzymes. When CCP2-3 of DAF were oriented according to the crystal structure of CCP1-2 of membrane cofactor protein, the essential residues formed a contiguous region, suggesting a similar spatial relationship.
- Published
- 2001
- Full Text
- View/download PDF
35. Molecular identification of Knops blood group polymorphisms found in long homologous region D of complement receptor 1.
- Author
-
Moulds JM, Zimmerman PA, Doumbo OK, Kassambara L, Sagara I, Diallo DA, Atkinson JP, Krych-Goldberg M, Hauhart RE, Hourcade DE, McNamara DT, Birmingham DJ, Rowe JA, Moulds JJ, and Miller LH
- Subjects
- Animals, Blood Group Antigens immunology, Blood Grouping and Crossmatching, Erythrocytes immunology, Humans, Plasmodium falciparum, Polymorphism, Genetic, Receptors, Complement 3b immunology, Blood Group Antigens genetics, Receptors, Complement 3b genetics
- Abstract
Complement receptor 1 (CR1) has been implicated in rosetting of uninfected red blood cells to Plasmodium falciparum-infected cells, and rosette formation is associated with severe malaria. The Knops blood group (KN) is located on CR1 and some of these antigens, ie, McCoy (McC) and Swain-Langley (Sl(a)), show marked frequency differences between Caucasians and Africans. Thus, defining the molecular basis of these antigens may provide new insight into the mechanisms of P falciparum malaria. Monoclonal antibody epitope mapping and serologic inhibition studies using CR1 deletion constructs localized McC and Sl(a) to long homologous repeat D of CR1. Direct DNA sequencing of selected donors identified several single nucleotide polymorphisms in exon 29 coding for complement control protein modules 24 and 25. Two of these appeared to be blood group specific: McC associated with K1590E and Sl(a) with R1601G. These associations were confirmed by inhibition studies using allele-specific mutants. A sequence-specific oligonucleotide probe hybridization assay was developed to genotype several African populations and perform family inheritance studies. Concordance between the 1590 mutation and McC was 94%; that between Sl(a) and 1601 was 88%. All but 2 samples exhibiting discrepancies between the genotype and phenotype were found to be due to low red cell CR1 copy numbers, low or absent expression of some alleles, or heterozygosity combined with low normal levels of CR1. These data further explain the variability observed in previous serologic studies of CR1 and show that DNA and protein-based genetic studies will be needed to clarify the role of the KN antigens in malaria.
- Published
- 2001
- Full Text
- View/download PDF
36. Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases.
- Author
-
Krych-Goldberg M, Hauhart RE, Subramanian VB, Yurcisin BM 2nd, Crimmins DL, Hourcade DE, and Atkinson JP
- Subjects
- Amino Acid Sequence, Binding Sites, Complement Pathway, Alternative physiology, Complement Pathway, Classical physiology, Conserved Sequence, Molecular Sequence Data, Mutagenesis, Site-Directed, Peptide Fragments genetics, Peptide Fragments metabolism, Receptors, Complement 3b genetics, Recombinant Proteins metabolism, Repetitive Sequences, Amino Acid, Complement Activation physiology, Complement C3-C5 Convertases metabolism, Receptors, Complement 3b metabolism
- Abstract
The goal of this study was to identify the site(s) in CR1 that mediate the dissociation of the C3 and C5 convertases. To that end, truncated derivatives of CR1 whose extracellular part is composed of 30 tandem repeating modules, termed complement control protein repeats (CCPs), were generated. Site 1 (CCPs 1-3) alone mediated the decay acceleration of the classical and alternative pathway C3 convertases. Site 2 (CCPs 8-10 or the nearly identical CCPs 15-17) had one-fifth the activity of site 1. In contrast, for the C5 convertase, site 1 had only 0.5% of the decay accelerating activity, while site 2 had no detectable activity. Efficient C5 decay accelerating activity was detected in recombinants that carried both site 1 and site 2. The activity was reduced if the intervening repeats between site 1 and site 2 were deleted. The results indicate that, for the C5 convertases, decay accelerating activity is mediated primarily by site 1. A properly spaced site 2 has an important auxiliary role, which may involve its C3b binding capacity. Moreover, using homologous substitution mutagenesis, residues important in site 1 for dissociating activity were identified. Based on these results, we generated proteins one-fourth the size of CR1 but with enhanced decay accelerating activity for the C3 convertases.
- Published
- 1999
- Full Text
- View/download PDF
37. Decay acceleration of the complement alternative pathway C3 convertase.
- Author
-
Hourcade DE, Mitchell LM, and Medof ME
- Subjects
- CD55 Antigens immunology, Complement C3-C5 Convertases immunology, Complement Factor H genetics, Complement Factor H immunology, Complement Factor H metabolism, Complement Pathway, Alternative immunology, Enzyme-Linked Immunosorbent Assay, Humans, Immune Adherence Reaction, Kinetics, Mutagenesis, Site-Directed, CD55 Antigens metabolism, Complement C3-C5 Convertases metabolism, Complement Pathway, Alternative physiology
- Abstract
An ELISA-based method is described for analyzing the mechanism by which the decay of the alternative pathway C3 convertase is accelerated by C3 regulatory proteins. Using this assay, we show that human decay-accelerating factor (DAF) and factor H are active on mature convertase complexes (C3bBb) but not on their nascent precursor (C3bB). This finding has implications on the mechanisms of action of these two regulators. The complement convertases cleave the serum protein C3, and the resulting C3b activation fragments covalently attach to nearby targets where they direct antigen selection, immune clearance, and cell lysis. Several proteins, including the membrane protein DAF, and the serum protein factor H, limit convertase activity by promoting their irreversible dissociation. An understanding of the biochemical mechanisms providing for their activities would be helpful for the therapeutic control of the complement response.
- Published
- 1999
- Full Text
- View/download PDF
38. Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding.
- Author
-
Hourcade DE, Mitchell LM, and Oglesby TJ
- Subjects
- Amino Acid Sequence, Animals, Binding Sites, COS Cells, Complement Factor B chemistry, Humans, Magnesium metabolism, Molecular Sequence Data, Structure-Activity Relationship, Complement C3b metabolism, Complement Factor B metabolism
- Abstract
Factor B is a zymogen that carries the catalytic site of the complement alternative pathway convertases. During C3 convertase assembly, factor B associates with C3b and is cleaved at a single site by factor D. The Ba fragment is released, leaving the active complex, C3bBb. During the course of this process, the protease domain becomes activated. The type A domain of factor B, also part of Bb, is similar in structure to the type A domain of the complement receptor and integrin, CR3. Previously, mutations in the factor B type A domain were described that impair C3b-binding. This report describes "gain of function" mutations obtained by substituting factor B type A domain amino acids with homologous ones derived from the type A domain of CR3. Replacement of the betaA-alpha1 Mg2+ binding loop residue D254 with smaller amino acids, especially glycine, increased hemolytic activity and C3bBb stability. The removal of the oligosaccharide at position 260, near the Mg2+ binding cleft, when combined with the D254G substitution, resulted in increased affinity for C3b and iC3b, a C3b derivative. These findings offer strong evidence for the direct involvement of the type A domain in C3b binding, and are suggestive that steric effects of the D254 sidechain and the N260-linked oligosaccharide may contribute to the regulation of ligand binding.
- Published
- 1999
39. A conserved element in the serine protease domain of complement factor B.
- Author
-
Hourcade DE, Mitchell LM, and Oglesby TJ
- Subjects
- Amino Acid Sequence, Binding Sites genetics, Complement C2 metabolism, Complement C3b metabolism, Complement Factor B genetics, Complement Factor D metabolism, Hemolysis genetics, Humans, Molecular Conformation, Molecular Sequence Data, Point Mutation genetics, Properdin pharmacology, Protein Binding genetics, Recombinant Proteins chemistry, Sequence Homology, Amino Acid, Serine Endopeptidases chemistry, Substrate Specificity, Complement Factor B chemistry, Conserved Sequence genetics
- Abstract
Factor B and C2 are serine proteases that carry the catalytic sites of the complement C3 and C5 convertases. Their protease domains are activated by conformational changes that occur during convertase assembly and are deactivated upon convertase dissociation. Factor B and C2 share an 8-amino acid conserved sequence near their serine protease termini that is not seen in other serine proteases. To determine its importance, 24 factor B mutants were generated, each with a single amino acid substitution in this region. Whereas most mutants were functionally neutral, all five different substitutions of aspartic acid 715 and one phenylalanine 716 substitution severely reduced hemolytic activity. Several aspartic acid 715 mutants permitted the steps of convertase assembly including C3b-dependent factor D-mediated cleavage and activation of the high affinity C3b-binding site, but the resulting complexes did not cleave C3. Given that factor B and C2 share the same biological substrates and that part of the trypsin-like substrate specificity region is not apparent in either protein, we propose that the conserved region plays a critical role in the conformational regulation of the catalytic site and could offer a highly specific target for the therapeutic inhibition of complement.
- Published
- 1998
- Full Text
- View/download PDF
40. Analysis of the short consensus repeats of human complement factor B by site-directed mutagenesis.
- Author
-
Hourcade DE, Wagner LM, and Oglesby TJ
- Subjects
- Amino Acid Sequence, Antibodies, Monoclonal, Base Sequence, Binding Sites genetics, Complement Factor B immunology, Complement Factor B metabolism, DNA Primers genetics, DNA, Complementary genetics, DNA, Complementary isolation & purification, Epitope Mapping, Hemolysis, Humans, Molecular Sequence Data, Mutagenesis, Site-Directed, Oligodeoxyribonucleotides genetics, Recombinant Proteins genetics, Recombinant Proteins immunology, Recombinant Proteins metabolism, Complement Factor B genetics, Consensus Sequence, Repetitive Sequences, Nucleic Acid
- Abstract
Human factor B is required for the initiation and propagation of the complement alternative pathway. It also participates in the amplification of the complement classical pathway. Alone, factor B is a zymogen with little known biochemical activity, but in the context of the alternative pathway convertases, the factor B serine protease is activated in a process that first involves the association with C3b and subsequently the cleavage of factor B into two fragments, Ba and Bb. Ba, the NH2-terminal fragment, is composed mainly of three tandem short consensus repeats, globular domains found in other complement proteins. It dissociates from the convertase during assembly, leaving the active C3 convertase, C3bBb. Previous reports suggest that the Ba region may be instrumental in convertase assembly. This hypothesis was tested using site-directed mutagenesis of recombinant factor B and monoclonal antibody epitope mapping to evaluate the relative importance of specific short consensus repeat amino acid residues. Three sites of interest were identified. Site 1 is a stretch of 19 contiguous amino acids in short consensus repeat 1 that form the epitope of a monoclonal antibody that effectively blocks factor B function. Site 2, composed of 6 contiguous amino acids in short consensus repeat 2, and site 3, consisting of 7 contiguous amino acids in short consensus repeat 3, were defined by mutations that reduce factor B hemolytic activity to 3% or less. Further analyses indicated that sites 2 and 3 contribute to factor B-C3b interactions.
- Published
- 1995
- Full Text
- View/download PDF
41. Marker rescue from bleomycin-treated Chlamydomonas reinhardi.
- Author
-
Hourcade DE
- Subjects
- Chlamydomonas genetics, Genes drug effects, Bleomycin pharmacology, Chromosomes drug effects, Genetic Markers drug effects, Genetic Techniques, Recombination, Genetic
- Abstract
A new method has been developed for gene transfer in eukaryotic cells. Chlamydomonas reinhardi, a unicellular eukaryotic alga, was treated with a lethal dose of bleomycin, an agent that induces chromosome breakage. Bleomycin-treated cells were mated with untreated cells, and the mixture was plated onto selective agar medium. The progeny that arose contained the genetic markers from the untreated parent plus a subset of the genetic markers from the bleomycin-treated parent. Those markers derived from the untreated parent were stable, whereas those recovered from the bleomycin-treated parent were often unstable. Markers closely linked in the bleomycin-treated parent were usually rescued or lost together, whereas distantly linked or unlinked markers were rescued or lost independently. These results suggest that bleomycin treatment of C. reinhardi leads to the formation of chromosome fragments, and fusion of bleomycin-treated cells to untreated cells results in the rescue of some of these fragments. This procedure provides a new means of gene transfer that may be useful for genetic mapping, genetic engineering and for the study of genetic organization.
- Published
- 1983
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.